Obulytix
Building the future of antibiotics
Ghent, Belgium · Founded 2023
- Headquarters
- Ghent
- Founded
- 2023
- Business Model
- B2B
- Website
- obulytix.com
- Last Round
- SeedDec 2023
- Rounds
- 1
About
Obulytix is a Belgium-based preclinical biotech, founded in 2023 as a spin-off from Ghent University and KU Leuven, that develops Precision Lysin Therapeutics as next-generation antibiotics. The company engineers phage-derived lysins—enzymes that cleave bacterial cell walls with high specificity—to treat multidrug-resistant Gram-negative infections and antimicrobial resistance, including infection control in cancer care. It is backed by Boehringer Ingelheim Venture Fund, Qbic Fund, and Gemma-Frisius Fund.
Summary
Obulytix is a Biotech company based in Ghent, Belgium, founded in 2023. Its most recent funding was a Seed round in Dec 2023. Investors include Boehringer Ingelheim Venture Fund.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2023
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/obulytix"><img src="https://indexed.vc/api/badge/company/obulytix" alt="Obulytix on Indexed.vc" width="260" height="76" /></a>